Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Comment on T-1249
Feb 10, 2004

I am a little disappointed to hear that Trimeris is discontinuing its development of T-1249. Supposedly this drug would be effective against resistent virus to T-20. From what I understand their reason is simply because T-20 has failed to generate alot of sales/profits. It just seems that if a product is known to benefit sick people they shold be forced to produce it. My question is... What can I do to fight against unjustices such as this.

Response from Dr. Wohl

Thanks for sharing your concern with us. The company states that they had hoped that T-1249 would be administered less frequently than it is but that has not worked out. There are also issues with production.

I suggest you ask them about these statements and express your dissatisfaction by writing or emailing Roche, the parent company. Find the addresses relevant to where you live at www.roche.com.

Thanks



Previous
are they sure?
Next
One Month Update

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement